Don’t Miss Out on the Pot Boom and Buy Canopy Growth (TSX:WEED) Now

Get ready for the marijuana boom’s next leg up and buy Canopy Growth Corp (TSX:WEED)(NYSE:CGC).

| More on:

Canada’s booming marijuana industry has been attracting considerable attention, especially since it became the first developed nation to legalize the recreational use of the drug. That event triggered a massive boom among marijuana companies with Canopy Growth (TSX:WEED)(NYSE:CGC) emerging as the industry leader.

The marijuana cultivator has grown from being the first publicly traded marijuana company in North America in early 2014 to now have a market cap of almost $20 billion and poised to enter the S&P/TSX 60 Index. This is a remarkable achievement and highlights why now is the time for investors to add Canopy to their portfolios.

Further market opportunities

Canopy is focused on ramping up its business and expanding at a rapid clip to be the world’s leading cultivator and distributor of marijuana products. The legalization of recreational marijuana use in Canada has also increased pressure south of the border for its recreational consumption to be fully legalized.

Currently, medical consumption of the drug has been legalized in 33 states and 10 of those states, notably California, legally allow recreational use, although marijuana is still illegal under federal law. While it may take some time for the drug to be fully legalized in the U.S., it is unlikely that such a burgeoning industry recognized in other developed nations will remain constrained by legalization for long. When it can be finally be legally consumed recreationally in the U.S. it will be a massive boon for an industry that is growing at a substantial rate.

Because of Canopy’s size and the maturity of its operations compared to its peers, it is well positioned to take full advantage of that development.

Growing distribution

The leading marijuana grower is working on a range of innovative initiatives aimed at increasing its distribution footprint and access to markets. This includes an alliance with Alimentation Couche-Tard to open a marijuana store in Ontario, which could lead to it being able to piggyback on Alimentation’s success in profitably operating a national chain of convenience stores.

As of April 1, 2019, appropriately licensed brick-and-mortar pot stores could open in Ontario. The number of locations was capped with only 25 licences available. This will boost its retail footprint, adding to the 28 stores already open in Saskatchewan, Manitoba, and Newfoundland.

Scaling up production

Canopy is focused on scaling up its growing activities with 4.3 million square feet of licensed capacity and the development of 1.3 million square feet underway. It also has 32 patents and 140 patent applications, which strengthen its position and will help Canopy build a wide economic moat.

The company’s leading position means it can build a formidable economic moat in an industry that will become easier to enter over time as the consumption and use of marijuana becomes more acceptable.

That enhances its long-term growth potential.

Canopy already has agreements in place to supply 70,000 kg of marijuana and that could easily double or even triple with the uptake of the drug expected to boom as it becomes more mainstream and widely accepted. A major single event, such as the U.S. removing the remaining legal barriers to the consumption of marijuana, would easily cause demand to expand exponentially.

Nonetheless, marijuana has never been commercially grown on the scale envisaged by Canopy, and that comes with risks. In such an intense growing environment, hundreds of plants can be lost through disease or poor growing conditions. There have, according to the Financial Post, been incidents where Canopy has lost large volumes of plants at its facilities.

What does it mean for investors?

Cannabis cultivation remains a high-risk industry because of a range of regulatory and legal unknowns, lack of maturity, and the social overhang associated with the negative perception associated with marijuana use. Those elements are changing, and Canopy is well positioned to capitalize on the expanding use of cannabis in our daily lives, which, with it being the leading Canadian cultivator, makes it the premier stock for investors seeking exposure to marijuana.

Fool contributor Matt Smith has no position in any of the stocks mentioned. Couche-Tard is a recommendation of Stock Advisor Canada.

More on Cannabis Stocks

four people hold happy emoji masks
Dividend Stocks

Wary of Mining Companies? A Lower-Risk Way to Get in on the Gold and Silver Surge

Frenco-Nevada (TSX:FNV) stock might be a wiser way to play the run in gold prices this year.

Read more »

Cannabis smoke
Cannabis Stocks

Have Cannabis Stocks Totally Gone Up in Smoke?

Let's dive into whether Canadian cannabis stocks are still investable, and what investors should make of the recent volatility in…

Read more »

Researcher works in hemp field
Cannabis Stocks

1 Undervalued Cannabis Stock to Buy and Hold Over the Next Decade

Green Thumb is a beaten-down cannabis stock that trades at a compelling valuation in September 2025.

Read more »

Researcher works in hemp field
Cannabis Stocks

Pot Stocks Rallied Hard in August: Is There More to Come?

Tilray Brands (TSX:TLRY) and the broad basket of pot stocks could heat up from here.

Read more »

Pot stocks are a riskier investment
Cannabis Stocks

Canopy Growth Stock Jumped 30% Last Month: What’s Going on?

Canopy Growth (TSX:WEED) stock is picking up traction again, making it an enticing weed play to buy on strength.

Read more »

A cannabis plant grows.
Cannabis Stocks

These Threats Facing Canopy Growth Stock Could Justify Selling it

Let's dive into whether Canopy Growth (TSX:WEED) is a top stock investors should buy right now after its recent dip…

Read more »

A person holds a small glass jar of marijuana.
Stocks for Beginners

This BioCannabis Firm Could Explode with Product Approval

This cannabis stock used to be a major name, so where does it stand now?

Read more »

Medicinal research is conducted on cannabis.
Stocks for Beginners

This TSX Health-Care Stock Is a Long-Term Buy for Patient Investors

This TSX stock continues to be one of the best long-term opportunities, if you're patient.

Read more »